Publications by authors named "Chung Ryeol Kim"
Article Synopsis
- The study evaluated the antiviral effectiveness and safety of a new drug, LB80380, in patients with chronic hepatitis B who were resistant to lamivudine.
- Sixty-five patients received escalating doses of LB80380 in combination with lamivudine, showing a significant reduction in HBV DNA levels, with over 93% experiencing a notable decrease.
- The drug was found to be safe and well tolerated, with mild side effects reported, and proved to effectively lower viral loads over the 12-week study period.
LB80380, a dipivoxil ester prodrug of LB80331 (metabolite, LB80317), is a novel antiviral agent for chronic hepatitis B (CHB). The pharmacokinetics of LB80331/LB80317 were evaluated in two clinical studies and a study with mice. The clinical studies were dose-escalating pharmacokinetic studies with six healthy subjects per single-dose group and six CHB patients per repeated-dose group.
View Article and Find Full Text PDFBackground: LB80380 is potent antiviral agent against hepatitis B virus (HBV) in vitro and in the woodchuck model. It has an excellent preclinical safety profile including lower potential for renal toxicity than adefovir. It is effective against both wild-type and YMDD mutant HBV.
View Article and Find Full Text PDF